Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse systemic sclerosis
Seminars in Arthritis and Rheumatism Jun 27, 2019
Mendoza FA, et al. - Twenty-five patients with recent-onset of rapidly progressive diffuse cutaneous systemic sclerosis (rp-dcSSc) were assessed by the researchers in order to characterize the clinical evolution of rp-dcSSc patients who were successfully treated with Mycophenolate Mofetil (MMF) following MMF therapy discontinuation or dose reduction. Five patients developed a relapse of rapid skin involvement with an average of 35.9% increase in modified Rodnan skin score from 7.8 to 10.6 points, out of 19 patients who were serially assessed following MMF discontinuation or dose reduction, requiring MMF re-institution. Worsening respiratory symptoms and reduction of lung volumes in pulmonary function tests (PFTs) were observed in 2 patients. The mRSS restored to baseline or steadied and PFTs improved or stabilized post-MMF resumption. Hence, 26.3% of patients exhibited recurrence of severe skin involvement with rp-dcSSc following MMF discontinuation or dose decrease and required immediate MMF therapy resumption. Further, the therapeutic benefit of MMF in rp-dcSSc was confirmed in this study suggesting MMF treatment maintenance for longer than 2 years.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries